Moderna (MRNA) Expected to Announce Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Friday, August 1st. Analysts expect Moderna to post earnings of ($2.97) per share and revenue of $116.26 million for the quarter.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period in the prior year, the business earned ($3.07) EPS. The firm’s quarterly revenue was down 35.3% on a year-over-year basis. On average, analysts expect Moderna to post $-10 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Moderna Trading Down 1.6%

Shares of NASDAQ:MRNA opened at $32.15 on Thursday. Moderna has a 52 week low of $23.15 and a 52 week high of $122.45. The company’s 50 day moving average is $29.14 and its two-hundred day moving average is $30.38. The company has a market cap of $12.43 billion, a PE ratio of -3.68 and a beta of 1.84.

Institutional Trading of Moderna

A number of institutional investors have recently added to or reduced their stakes in MRNA. Focus Partners Wealth increased its position in shares of Moderna by 58.7% during the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after purchasing an additional 8,706 shares during the last quarter. United Services Automobile Association bought a new position in shares of Moderna during the 1st quarter valued at about $230,000. NewEdge Advisors LLC grew its position in Moderna by 732.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock worth $328,000 after acquiring an additional 10,185 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Moderna during the 1st quarter worth approximately $415,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MRNA. Cowen initiated coverage on shares of Moderna in a research note on Sunday, July 13th. They issued a “hold” rating for the company. JPMorgan Chase & Co. reduced their target price on shares of Moderna from $33.00 to $26.00 and set an “underweight” rating on the stock in a research report on Thursday, May 22nd. Barclays restated an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research note on Sunday, July 13th. Finally, UBS Group reduced their target price on shares of Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Four research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $46.11.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.